Sorry, you need to enable JavaScript to visit this website.
  1. Home
  3. Science
  4. Clinical Trials
  5. Plain Language Study Results Summaries
  6. Study Evaluate Effect Gbt440 Tcd

Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease (HOPE Kids 2)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants With Sickle Cell Disease (HOPE Kids 2)

Category & Conditions: Rare Diseases
Medicine: OXBRYTA(VOXELOTOR)
ClinicalTrials.gov Identifier (NCT): NCT04218084
Protocol ID: C5341021 (GBT440-032)
DownloadPrint

Open Plain Language Summary Result:

Click here